Our Products
For Pulmonary Hypertension
TNX-201 (oral enteric coated imatinib)
in PAH
- Imatinib already proven effective for PAH in a Phase 3 trial
- Novel oral formulation development to mitigate previous problem of gastric intolerance
- FDA Agreement for our improved, enriched trial design requiring fewer patients
- Potential first disease-modifying drug for PAH
TNX-103 (oral levosimendan)
in PH-HFpEF
- Levosimendan approved safe and effective for acute decompensated heart failure in 60+ countries since 2000
- Intravenous levosimendan first treatment to show efficacy in PH-HFpEF in the Tenax Phase 2 trial
- FDA agreement to use oral levosimendan formulation in Phase 3 development program
- Discovery of levosimendan’s novel mechanism of action and treatment target makes it uniquely effective for HFpEF patients
TNX-201 (oral enteric coated imatinib)
in PAH
LEARN MORE BELOW
TNX-103 (oral levosimendan)
in PH-HFpEF
LEARN MORE BELOW
